Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer

  • Authors:
    • Ying Cheng
    • Yun Fan
    • Xiaoqing Liu
    • Yunpeng Liu
    • Jiwei Liu
    • Dong Wang
    • Yan Yu
    • Shukui Qin
    • Wei Liu
    • Cheng Huang
    • Helong Zhang
    • Jun Liang
    • Jianhua Shi
    • Lijun Sheng
    • Hao Yu
  • View Affiliations

  • Published online on: March 8, 2019     https://doi.org/10.3892/ol.2019.10125
  • Pages: 4701-4709
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The majority of previous studies of lobaplatin in small cell lung cancer (SCLC) are small phase I‑II studies. The present study aimed to verify the non‑inferiority (in terms of efficacy) of lobaplatin plus etoposide (EL) vs. cisplatin plus etoposide (EP) in patients with previously untreated extensive‑stage SCLC (ES‑SCLC). This phase III non‑inferiority randomized clinical trial enrolled patients at 17 sites between September 2010 and May 2013. Patients were randomized to EL (30 mg/m2 lobaplatin on day 1 and 100 mg/m2 etoposide on days 1‑3, for 21‑day cycles) or EP (80 mg/m2 cisplatin on day 1 and 100 mg/m2 etoposide on days 1‑3, for 21‑day cycles). The primary endpoint was progression‑free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, disease control rate (DCR), toxicity and quality of life (QoL). A total of 234 patients were randomized to the EL (n=122) and EP (n=112) treatment groups. The median PFS, median OS and DCR were 5.1 vs. 5.3 months (P=0.786), 10.6 vs. 9.7 months (P=0.701) and 85.5 vs. 86.7% (P=0.848) in the EL vs. EP groups, respectively. Patients in the EL group had significantly lower frequencies of nephrotoxicity (2.5 vs. 11.7%; P=0.008), nausea (22.3 vs. 40.5%; P=0.003) and vomiting (14.1 vs. 35.1%; P<0.001) than those in the EP group. Overall, EL was not inferior to EP in terms of PFS and OS. The tolerance and QoL of the EL regimen were better than those of the EP regimen. EL is thus an alternative choice for the first‑line treatment of ES‑SCLC.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 17 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cheng Y, Fan Y, Liu X, Liu Y, Liu J, Wang D, Yu Y, Qin S, Liu W, Huang C, Huang C, et al: Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer. Oncol Lett 17: 4701-4709, 2019.
APA
Cheng, Y., Fan, Y., Liu, X., Liu, Y., Liu, J., Wang, D. ... Yu, H. (2019). Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer. Oncology Letters, 17, 4701-4709. https://doi.org/10.3892/ol.2019.10125
MLA
Cheng, Y., Fan, Y., Liu, X., Liu, Y., Liu, J., Wang, D., Yu, Y., Qin, S., Liu, W., Huang, C., Zhang, H., Liang, J., Shi, J., Sheng, L., Yu, H."Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer". Oncology Letters 17.5 (2019): 4701-4709.
Chicago
Cheng, Y., Fan, Y., Liu, X., Liu, Y., Liu, J., Wang, D., Yu, Y., Qin, S., Liu, W., Huang, C., Zhang, H., Liang, J., Shi, J., Sheng, L., Yu, H."Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer". Oncology Letters 17, no. 5 (2019): 4701-4709. https://doi.org/10.3892/ol.2019.10125